H Westekemper1, S L Scholz2, H Thomasen2, C Halfwassen2, K-P Steuhl2. 1. Klinik für Augenheilkunde, Universitätsklinikum Essen, Hufelandstr. 55, 45134, Essen, Deutschland. Henrike.westekemper@uk-essen.de. 2. Klinik für Augenheilkunde, Universitätsklinikum Essen, Hufelandstr. 55, 45134, Essen, Deutschland.
Abstract
BACKGROUND: Ocular graft-versus-host disease (GvHD) following allogeneic blood stem cell transplantation leads to immunologically induced alterations in many ocular tissues, particularly at the ocular surface. Within the framework of the main topic, this article focuses primarily on corneal complications in chronic ocular GvHD. OBJECTIVE: This article aims to promote understanding of the influencing factors, diagnostics, and therapeutic options pertaining to corneal complications in ocular GvHD. Furthermore, the possibilities for prevention are discussed. MATERIALS AND METHODS: This analysis is based on a literature review as well as on data from the Ophthalmology Clinic at the University Hospital Essen. RESULTS: Corneal complications often occur secondarily in ocular GvHD, as a consequence of severe inflammatory alterations of the conjunctiva or eyelid. Spontaneous corneal perforations associated with only mild symptoms are less common during the course of disease. From the ophthalmologist's perspective, it is important that the inflammatory activity of all the different ocular tissues is considered. Treatment may follow a stepwise scheme that includes substitution, immunosuppression, and surgical rehabilitation. CONCLUSION: Systematic diagnosis of ocular GvHD helps to prevent corneal complications or support early therapeutic intervention. An interdisciplinary approach to diagnosis and treatment planning is recommended, in order to optimize local and systemic immunosuppressive therapy.
BACKGROUND:Ocular graft-versus-host disease (GvHD) following allogeneic blood stem cell transplantation leads to immunologically induced alterations in many ocular tissues, particularly at the ocular surface. Within the framework of the main topic, this article focuses primarily on corneal complications in chronic ocular GvHD. OBJECTIVE: This article aims to promote understanding of the influencing factors, diagnostics, and therapeutic options pertaining to corneal complications in ocular GvHD. Furthermore, the possibilities for prevention are discussed. MATERIALS AND METHODS: This analysis is based on a literature review as well as on data from the Ophthalmology Clinic at the University Hospital Essen. RESULTS:Corneal complications often occur secondarily in ocular GvHD, as a consequence of severe inflammatory alterations of the conjunctiva or eyelid. Spontaneous corneal perforations associated with only mild symptoms are less common during the course of disease. From the ophthalmologist's perspective, it is important that the inflammatory activity of all the different ocular tissues is considered. Treatment may follow a stepwise scheme that includes substitution, immunosuppression, and surgical rehabilitation. CONCLUSION: Systematic diagnosis of ocular GvHD helps to prevent corneal complications or support early therapeutic intervention. An interdisciplinary approach to diagnosis and treatment planning is recommended, in order to optimize local and systemic immunosuppressive therapy.
Authors: Christiane Blecha; Daniel Wolff; Barbara Holler; Ernst Holler; Daniela Weber; Regine Vogt; Horst Helbig; Tina Dietrich-Ntoukas Journal: Ann Hematol Date: 2015-12-14 Impact factor: 3.673
Authors: Madan H Jagasia; Hildegard T Greinix; Mukta Arora; Kirsten M Williams; Daniel Wolff; Edward W Cowen; Jeanne Palmer; Daniel Weisdorf; Nathaniel S Treister; Guang-Shing Cheng; Holly Kerr; Pamela Stratton; Rafael F Duarte; George B McDonald; Yoshihiro Inamoto; Afonso Vigorito; Sally Arai; Manuel B Datiles; David Jacobsohn; Theo Heller; Carrie L Kitko; Sandra A Mitchell; Paul J Martin; Howard Shulman; Roy S Wu; Corey S Cutler; Georgia B Vogelsang; Stephanie J Lee; Steven Z Pavletic; Mary E D Flowers Journal: Biol Blood Marrow Transplant Date: 2014-12-18 Impact factor: 5.742
Authors: Rafael de Melo Franco; Michelle M Kron-Gray; Paola De la Parra-Colin; Yan He; David C Musch; Shahzad I Mian; Leslie Niziol; H Kaz Soong Journal: Cornea Date: 2015-05 Impact factor: 2.651
Authors: J T Seki; N Sakurai; S Moldenhauer; J Dam; E G Atenafu; P M Yip; T Mazzulli; T Henderson; J Pendergrast; C Cserti; J P Velazquez; R Simpson; G Felluga; H A Messner; J H Lipton Journal: Curr Oncol Date: 2015-10 Impact factor: 3.677
Authors: S Pezzotta; G C Rossi; L Scudeller; E Antoniazzi; P E Bianchi; C Perotti; C Del Fante Journal: Bone Marrow Transplant Date: 2015-06-08 Impact factor: 5.483
Authors: Y Wang; Y Ogawa; M Dogru; M Kawai; Y Tatematsu; M Uchino; N Okada; A Igarashi; A Kujira; H Fujishima; S Okamoto; J Shimazaki; K Tsubota Journal: Bone Marrow Transplant Date: 2007-11-05 Impact factor: 5.483